Fluoromount-G® DAPI 螢光封片劑 | Southernbiotech貨號0100-20
Fluoromount-G DAPI螢光封片劑 | 貨號: 0100-20 |規格20ml
Fluoromount-G® (Clear liquid mounting medium) Fluoromount-G抗螢光淬滅封片劑，內含DAPI核酸染劑，染核與封片同時進行；水溶性封片劑，內含螢光保護劑，可大幅減緩螢光分子氧化褪色的情形。
產品特點: SouthernBiotech(SBA) Fluoromount-G系列DAPI螢光封片劑 (抗淬滅封片劑)，操作簡便用於長時間保存玻片，有一定抗淬滅作用，適用組織切片、細胞塗片/爬片等實驗。提供二種型式之螢光封片劑 (貨號#0100-01)、與含有DAPI染劑之DAPI螢光封片劑 (貨號#0100-20)。 Fluoromount-G使用方法 組織切片: 免疫染色、脫水、透明; 加入1~2滴封片劑覆蓋組織，蓋上蓋玻片。用紗布片輕輕按壓，使得多餘的封片劑將蓋玻片周圍封住；玻片置於空氣中乾燥5min。產品狀態貯存: 水溶性透明液體，含0.1NaN3室溫避光貯存
| 產品型號 | 產品名稱 | 包裝 |
| 0100-01 | Fluoromount-G螢光封片劑 | 25 mL |
| 0100-20 | Fluoromount-G螢光封片劑 (DAPI) | 20 mL |
封片最佳化: 建議封片後，以指甲油固定蓋玻片以避免樣品風乾，塗指甲油前需先將溢出的封片膠擦掉，而塗抹時蓋玻片邊緣與載玻片都要確實塗到，確實達到固定與防漏的效果。用顯微鏡觀察前也務必確認指甲油已乾，以避免指甲油沾染到物鏡。
Frozen section of Pvalb-IRES-CRE mouse CA1 hippocampus injected with AAV-hM4Di-mCherry was stained with anti-parvalbumin followed by a secondary antibody and mounted with DAPI Fluoromount-G® (SB Cat. No. 0100-20).Image from Ognjanovski N, Schaeffer S, Wu J, Mofakham S, Maruyama D, Zochowski M, et al. Parvalbumin-expressing interneurons coordinate hippocampal network dynamics required for memory consolidation. Nat Commun. 2017;8:15039. Figure 2(a)
HEK293T cells transfected with p.G120C-mRFP-ICK were mounted with DAPI Fluoromount-G® (SB Cat. No. 0100-20).Image from Oud MM, Bonnard C, Mans DA, Altunoglu U, Tohari S, Ng AY, et al. A novel ICK mutation causes ciliary disruption and lethal endocrine-cerebro-osteodysplasia syndrome. Cilia. 2016;5:8. Figure 2(a)
BALB/c mouse intestine sections were stained with Rat Anti-Mouse MAdCAM-1-BIOT (SB Cat. No. 1865-08) followed by Streptavidin-FITC (SB Cat. No. 7100-02). Sections were mounted with DAPI-Fluoromount-G® (SB Cat. No. 0100-20).
Human cancer-associated fibroblasts 120 h post exposure to 18 Gy were stained with anti-vinculin followed by an AF488 conjugated secondary antibody and mounted with DAPI Fluoromount-G® (SB Cat. No. 0100-20). Image from Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, et al. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol. 2012;7:59. Figure 6(a)